Core Viewpoint - The article highlights Siemens Healthineers' commitment to localizing its operations in China while introducing innovative medical technologies, aiming to transition from a product provider to a value partner in the healthcare sector [2][5][8]. Group 1: Localization and Innovation - Siemens Healthineers showcased multiple new products, including photon-counting CT devices, at the 8th China International Import Expo, emphasizing its strategy to bring global innovations to the Chinese market [2][3]. - The company has achieved over 80% localization in production, with more than 130 products manufactured locally, and plans to further enhance its local manufacturing capabilities [5][6]. - The introduction of the world's first photon-counting CT, NAEOTOM Alpha, represents a significant advancement, with plans for two new models to be produced in China by 2026 [5]. Group 2: Advanced Medical Solutions - The ARTIS icono ceiling Xpand system features a unique 0.5mm precision laser puncture navigation, significantly improving the accuracy of interventions for lung and liver cancers [3]. - The Biograph One PET/MR system allows simultaneous imaging of structural, functional, and molecular data, reducing scan times to 17 minutes, thus enhancing efficiency and accessibility [3]. - The SmART adaptive radiotherapy solution, designed for Chinese clinical needs, enables personalized treatment adjustments in real-time, improving patient outcomes [4]. Group 3: Strategic Collaborations and Future Plans - Siemens Healthineers has formed strategic partnerships, such as with Novartis, to explore integrated systems for molecular imaging and radioligand therapy, reinforcing its role as a value partner [7]. - The company is expanding its R&D and manufacturing base in Shenzhen, with an investment exceeding 1 billion RMB, aiming to triple the facility's capacity by 2027 [6]. - Siemens Healthineers plans to deepen its integration with clinical practices and enhance its sustainability efforts, focusing on creating a more open innovation ecosystem in China's healthcare sector [8].

2025 年 4 月 8 日， 春季 CMEF 展会 在上海如火如荼 ，思宇 MedTech 记者 探馆中， 注意到一个不寻常的现象： 在 西门子医疗的展台 上， 多款 创新设备几 乎覆盖了影像技术的所有关键临床节点 —— 从 110 微米分辨率的光子计数 CT NAEOTOM Alpha ，到 "自动驾驶" 的 C 臂 CT Ciartic Move 、极低辐射剂量的 PET/CT Biograph Vision Quadra 2.0 ，以及 配备创新超导 磁体 的 绿色磁共振系统 MAGNETOM Flow …… 这种高度聚合的创新组合 产品 ，即便在跨国企业中也属罕见。 为了一探究竟， 思宇 MedTech 采访 了 西门子医疗大中华区总裁、全球领导委员会成员 王皓 先生 ，想了解如此多款高度原创的产品是怎么做出来的。 王皓开门见山： 一句话，点破了核心问题：医疗设备的创新，不是单纯的技术指标、不是单一的产品，而是 形成协同创新的机制 ，从而不断诞生创新的产品。 # 医疗器械行业的创新逻辑：不是 "造出来"，而是"协作出来" 医疗器械不同于工业设备，它的核心价值不在于功能本身，而在于功能如何被临床 医生 ...